Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Anthony Vendetti maintains a Buy rating on Dermata Therapeutics but lowers the price target from $10 to $6.
August 21, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Maxim Group's analyst Anthony Vendetti maintains a Buy rating on Dermata Therapeutics but reduces the price target from $10 to $6, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in Dermata Therapeutics' potential, but the lowered price target reflects a more cautious outlook on its short-term performance. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100